Fresenius SE KGaA (XTRA:FRE) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

FRE Stoklara Genel Bakış

Fresenius SE & Co. KGaA, bir sağlık hizmetleri şirketi olarak kronik hastalara yönelik ürün ve hizmetler sunmaktadır.

FRE temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	3/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 61.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 23.72% oranında artması öngörülüyor

Risk Analizi

Faiz ödemeleri kazançlarla iyi karşılanmıyor

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Tokyo

Community Contributor

First comes the pain, then the money.

€74.00

54.2% undervalued

24.16%

Revenue growth p.a.

3 months ago

Fresenius SE & Co. KGaA Rakipler

Fresenius Medical Care

XTRA:FME

€11.1b

SYNLAB

HMSE:SYAB

€2.4b

Siemens Healthineers

XTRA:SHL

€57.8b

Carl Zeiss Meditec

XTRA:AFX

€6.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Fresenius SE KGaA
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€33.92
52 Haftanın En Yüksek Seviyesi	€35.03
52 Haftanın En Düşük Seviyesi	€23.93
Beta	1.07
11 Aylık Değişim	2.11%
3 Aylık Değişim	16.76%
1 Yıllık Değişim	20.84%
33 Yıllık Değişim	-16.43%
5 Yıllık Değişim	-19.70%
Halka arzdan bu yana değişim	2,904.45%

Son Haberler & Güncellemeler

Recent updates

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24

Is Now An Opportune Moment To Examine Fresenius SE & Co. KGaA (ETR:FRE)?

Jan 13

Here's Why Fresenius SE KGaA (ETR:FRE) Has A Meaningful Debt Burden

Dec 29

Hissedar Getirileri

	FRE	DE Healthcare	DE Pazar
7D	1.0%	-0.03%	-1.9%
1Y	20.8%	11.3%	12.3%

Getiri vs. Endüstri: FRE geçen yıl % 10 oranında getiri sağlayan German Healthcare sektörünü aştı.

Getiri vs Piyasa: FRE geçen yıl % 13.8 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement	2.9%
Healthcare Industry Average Movement	3.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: FRE son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: FRE 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1912	175,771	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, kronik hastalar için ürün ve hizmetler sağlayan bir sağlık hizmetleri şirketidir. Dört segment aracılığıyla faaliyet göstermektedir: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios ve Fresenius Vamed. Fresenius Medical Care segmenti, kronik böbrek yetmezliği olan hastalar için ürün ve hizmetler sunmaktadır.

Fresenius SE & Co. KGaA Temel Bilgiler Özeti

Fresenius SE KGaA'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
FRE temel i̇stati̇sti̇kler
Piyasa değeri	€19.11b
Kazançlar(TTM)	€721.00m
Gelir(TTM)	€22.63b

26.5x

F/K Oranı

0.8x

P/S Oranı

FRE aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
FRE gelir tablosu (TTM)
Gelir	€22.63b
Gelir Maliyeti	€17.41b
Brüt Kâr	€5.23b
Diğer Giderler	€4.51b
Kazançlar	€721.00m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 06, 2024

Hisse başına kazanç (EPS)	1.28
Brüt Marj	23.09%
Net Kâr Marjı	3.19%
Borç/Özkaynak Oranı	61.2%

FRE uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

FRE Stoklara Genel Bakış

Ödüller

Risk Analizi

First comes the pain, then the money.

Fresenius SE & Co. KGaA Rakipler

XTRA:FME

€11.1b

HMSE:SYAB

€2.4b

XTRA:SHL

€57.8b

XTRA:AFX

€6.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Consensus EPS estimates fall by 34%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Consensus EPS estimates fall by 34%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence